Edgewise Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Edgewise Therapeutics
EWTX Stock  USD 26.53  0.10  0.38%   
Edgewise Therapeutics financial statements provide useful quarterly and yearly information to potential Edgewise Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Edgewise Therapeutics financial statements helps investors assess Edgewise Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Edgewise Therapeutics' valuation are summarized below:
Market Capitalization
2.5 B
Earnings Share
(1.45)
We have found one hundred twenty available fundamental signals for Edgewise Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Edgewise Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 2.3 B in 2025. Enterprise Value is likely to rise to about 2.3 B in 2025
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 26.3 M, Interest Income of 26.3 M or Depreciation And Amortization of 2.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.64. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Edgewise Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets299.7 M486.8 M134.7 M
Slightly volatile
Short and Long Term Debt Total4.5 M4.7 M36.6 M
Pretty Stable
Other Current Liabilities8.8 M17.3 M3.8 M
Slightly volatile
Total Current Liabilities13.4 M23.9 M6.1 M
Slightly volatile
Property Plant And Equipment Net6.5 M11.1 M2.9 M
Slightly volatile
Accounts Payable4 M5.6 M2 M
Slightly volatile
Cash39.6 M41.7 M71.3 M
Slightly volatile
Non Current Assets Total8.4 M11.3 M3.7 M
Slightly volatile
Cash And Short Term Investments288.6 M470.2 M129.7 M
Slightly volatile
Common Stock Shares Outstanding65.6 M92.4 M54.1 M
Slightly volatile
Liabilities And Stockholders Equity299.7 M486.8 M134.7 M
Slightly volatile
Non Current Liabilities Total3.6 M3.7 M36.2 M
Pretty Stable
Other Current Assets5.7 M5.3 M2.5 M
Slightly volatile
Other Stockholder Equity879.2 M837.4 M195.4 M
Slightly volatile
Total Liabilities38.1 M27.6 M43.5 M
Very volatile
Property Plant And Equipment Gross16.5 M15.8 M3.9 M
Slightly volatile
Total Current Assets291.3 M475.5 M131 M
Slightly volatile
Net Working Capital279.4 M451.6 M125.6 M
Slightly volatile
Property Plant Equipment10.3 M9.8 M2.7 M
Slightly volatile
Non Currrent Assets Other248.9 K262 K1.3 M
Pretty Stable
Other Assets214.6 K225.9 K763.5 K
Slightly volatile
Deferred Long Term Liabilities380.4 K225.9 K566.2 K
Slightly volatile
Other Liabilities263.2 K296.1 K322.8 K
Slightly volatile
Net Receivables319.6 K225.9 K476.5 K
Slightly volatile
Common Stock Total Equity6 K6.9 K5.3 K
Slightly volatile
Capital Surpluse464.5 M566.6 M389.9 M
Slightly volatile
Non Current Liabilities Other263.2 K296.1 K322.8 K
Slightly volatile
Common Stock7.4 K9 K5.6 K
Slightly volatile
Short Term Debt851.2 K996 K1.2 M
Slightly volatile

Edgewise Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income26.3 M25 M4.5 M
Slightly volatile
Interest Income26.3 M25 M4.5 M
Slightly volatile
Depreciation And Amortization2.1 M2 M502.5 K
Slightly volatile
Selling General Administrative33.5 M31.9 M7.5 M
Slightly volatile
Other Operating Expenses138.1 M131.5 M35.4 M
Slightly volatile
Research Development133.3 M127 M31.2 M
Slightly volatile
Cost Of Revenue2.1 M2 M502.5 K
Slightly volatile
Total Operating Expenses166.8 M158.8 M38.9 M
Slightly volatile
Reconciled Depreciation2.4 M2.3 M540.7 K
Slightly volatile
Total Other Income Expense Net26.3 M25 M4.4 M
Slightly volatile
Non Operating Income Net Other2.4 M4.6 M1.2 M
Slightly volatile
Selling And Marketing Expenses144.8 K162.9 K177.6 K
Slightly volatile

Edgewise Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation25.9 M24.7 M5.3 M
Slightly volatile
Begin Period Cash Flow47.7 M86.1 M23.9 M
Slightly volatile
Other Cashflows From Financing Activities17.7 M10.1 M9.4 M
Pretty Stable
Depreciation2.4 M2.3 M540.7 K
Slightly volatile
Capital Expenditures2.5 M1.3 M1.1 M
Slightly volatile
Change To Operating Activities4.9 M4.6 M1.3 M
Slightly volatile
Total Cash From Financing Activities140 M249.3 M70.4 M
Slightly volatile
End Period Cash Flow53.9 M41.7 M35 M
Slightly volatile
Change To Netincome13.2 M12.6 M3.3 M
Slightly volatile
Change To Liabilities2.9 M3 M1.3 M
Slightly volatile
Sale Purchase Of Stock126.5 M116.9 M171.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.540.57292.0579
Pretty Stable
Payables Turnover0.410.390.2094
Slightly volatile
Cash Per Share4.935.08762.8873
Slightly volatile
Days Payables Outstanding9279752.2 K
Very volatile
Income Quality0.940.81480.9086
Slightly volatile
Current Ratio25.3819.92822.1855
Pretty Stable
Capex Per Share0.01350.01420.0172
Slightly volatile
Interest Debt Per Share0.04870.05130.7459
Pretty Stable
Debt To Assets0.00920.00971.1054
Slightly volatile
Days Of Payables Outstanding9279752.2 K
Very volatile
Ebt Per Ebit1.020.84250.9615
Slightly volatile
Effective Tax Rate0.20.190.0656
Slightly volatile
Long Term Debt To Capitalization0.00650.00730.0079
Slightly volatile
Total Debt To Capitalization0.00970.01021.1578
Slightly volatile
Quick Ratio25.3819.92822.1855
Pretty Stable
Net Income Per E B T1.030.910.955
Slightly volatile
Cash Ratio1.661.746318.0976
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.831.0121.015
Pretty Stable
Debt Ratio0.00920.00971.1054
Slightly volatile

Edgewise Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B2.2 B1 B
Slightly volatile
Enterprise Value2.3 B2.2 B797.1 M
Slightly volatile

Edgewise Fundamental Market Drivers

Cash And Short Term Investments470.2 M

Edgewise Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Edgewise Therapeutics Financial Statements

Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue2 M2.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY